Free Trial
NASDAQ:ZBIO

Zenas Biopharma (ZBIO) Stock Price, News & Analysis

Zenas Biopharma logo
$11.92 +0.36 (+3.11%)
As of 05/2/2025 04:00 PM Eastern

About Zenas Biopharma Stock (NASDAQ:ZBIO)

Key Stats

Today's Range
$11.53
$12.41
50-Day Range
N/A
52-Week Range
$5.83
$26.25
Volume
111,593 shs
Average Volume
192,177 shs
Market Capitalization
$498.66 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$40.00
Consensus Rating
Buy

Company Overview

Zenas BioPharma, Inc. is a clinical-stage global biopharmaceutical company. The firm is mainly engaged in the development and commercialization of transformative immunology-based therapies for patients. The company was founded by Lonnie O. Moulder Jr on November 12, 2019 and is headquartered in Waltham, MA.

Receive ZBIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Zenas Biopharma and its competitors with MarketBeat's FREE daily newsletter.

ZBIO Stock News Headlines

Blackrock’s Sending THIS Crypto Higher on Purpose
While everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly positioning itself to overthrow the entire banking system.
See More Headlines

ZBIO Stock Analysis - Frequently Asked Questions

Zenas Biopharma's stock was trading at $7.90 at the start of the year. Since then, ZBIO shares have increased by 50.9% and is now trading at $11.92.
View the best growth stocks for 2025 here
.

Zenas Biopharma (ZBIO) raised $225 million in an IPO on Friday, September 13th 2024. The company issued 13,235,294 shares at a price of $17.00 per share.

Zenas Biopharma's lock-up period expired on Wednesday, March 12th. Zenas Biopharma had issued 13,235,294 shares in its initial public offering on September 13th. The total size of the offering was $224,999,998 based on an initial share price of $17.00. Since the expiration of Zenas Biopharma's lock-up period, restrictions preventing major shareholders and company insiders from selling shares in the company have been lifted.

Zenas Biopharma's top institutional investors include Alps Advisors Inc. (0.07%), Rhumbline Advisers (0.03%) and New York State Common Retirement Fund (0.01%).

Shares of ZBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Zenas Biopharma investors own include AST SpaceMobile (ASTS), Tempus AI (TEM), Trade Desk (TTD), Advanced Micro Devices (AMD), BioSig Technologies (BSGM), Ford Motor (F) and Genius Sports (GENI).

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:ZBIO
Previous Symbol
NASDAQ:ZBIO
Web
N/A
Fax
N/A
Employees
N/A
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$40.00
High Stock Price Target
$45.00
Low Stock Price Target
$35.00
Potential Upside/Downside
+235.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$5 million
Price / Cash Flow
N/A
Price / Book
N/A

Miscellaneous

Free Float
N/A
Market Cap
$498.66 million
Optionable
N/A
Beta
N/A
7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025 Cover

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report

This page (NASDAQ:ZBIO) was last updated on 5/5/2025 by MarketBeat.com Staff
From Our Partners